{"id":790,"date":"2017-02-26T19:12:39","date_gmt":"2017-02-26T19:12:39","guid":{"rendered":"https:\/\/www.progeriaresearch.org\/?page_id=790"},"modified":"2026-03-17T11:43:56","modified_gmt":"2026-03-17T15:43:56","slug":"lonafarnib-pre-clinical-drug-supply-program","status":"publish","type":"page","link":"https:\/\/www.progeriaresearch.org\/fr\/lonafarnib-pre-clinical-drug-supply-program\/","title":{"rendered":"Programme d'approvisionnement en m\u00e9dicaments pr\u00e9cliniques Lonafarnib"},"content":{"rendered":"

[et_pb_section fb_built=\u201d1\u2033 fullwidth=\u201don\u201d disabled_on=\u201doff|off|off\u201d _builder_version=\u201d4.16\u2033 border_width_bottom=\u201d55px\u201d border_color_bottom=\u201d#29327a\u201d locked=\u201doff\u201d global_colors_info=\u201d{}\u201d][et_pb_fullwidth_header _builder_version=\u201d4.18.1\u2033 title_font=\u201d||||||||\u201d title_font_size=\u201d55\u2033 background_color=\u201d#29327a\u201d background_image=\u201dhttps:\/\/www.progeriaresearch.org\/wp-content\/uploads\/2020\/12\/Aluisio.jpg\u201d background_position=\u201dcenter_left\u201d custom_padding=\u201d9vw||9vw||true\u201d custom_padding_tablet=\u201d\u201d custom_padding_phone=\u201d|56px||\u201d custom_padding_last_edited=\u201don|desktop\u201d title_font_size_tablet=\u201d45px\u201d title_font_size_phone=\u201d40px\u201d title_font_size_last_edited=\u201don|phone\u201d z_index_tablet=\u201d500\u2033 custom_css_main_element=\u201dbackground-position: center 18% !important;\u201d global_colors_info=\u201d{}\u201d]<\/p>\n

\u00c9tude pr\u00e9clinique sur le lonafarnib<\/h1>\n

Programme d'approvisionnement en m\u00e9dicaments<\/h1>\n

 <\/p>\n

[\/et_pb_fullwidth_header][\/et_pb_section][et_pb_section fb_built=\u201d1\u2033 use_custom_gutter=\u201don\u201d gutter_width=\u201d1\u2033 specialty=\u201don\u201d padding_left_1=\u201d35px\u201d padding_left_2=\u201d35px\u201d padding_2_tablet=\u201d|||0px\u201d padding_2_phone=\u201d|||0px\u201d padding_2_last_edited=\u201don|desktop\u201d module_class_1=\u201dsidebar-secondary-nav\u201d module_class=\u201dempreinte-de-la-main-bg\u201d _builder_version=\u201d4.16\u2033 background_image=\u201dhttps:\/\/www.progeriaresearch.org\/wp-content\/uploads\/2019\/04\/empreinte-de-la-main-bleue-uniquement.png\u201d parallax=\u201don\u201d parallax_method=\u201doff\u201d inner_width=\u201d100%\u201d inner_max_width=\u201d100%\u201d custom_padding=\u201d0|0px|54px|0px|false|false\u201d z_index_tablet=\u201d500\u2033 border_width_top=\u201d10px\u201d border_color_top=\u201d#8fd2ed\u201d use_custom_width=\u201don\u201d width_unit=\u201doff\u201d custom_width_percent=\u201d100%\u201d global_colors_info=\u201d{}\u201d][et_pb_column type=\u201d1_4\u2033 _builder_version=\u201d4.16\u2033 custom_padding=\u201d|||\u201d global_colors_info=\u201d{}\u201d custom_padding__hover=\u201d|||\u201d][et_pb_sidebar area=\u201det_pb_widget_area_14\u2033 disabled_on=\u201don|on|off\u201d module_class=\u201dsubpage-sidebars\u201d _builder_version=\u201d4.16\u2033 animation_style=\u201dfade\u201d z_index_tablet=\u201d500\u2033 border_width_right=\u201d5px\u201d locked=\u201doff\u201d global_colors_info=\u201d{}\u201d]
\n[\/et_pb_sidebar][\/et_pb_column][et_pb_column type=\u201d3_4\u2033 specialty_columns=\u201d3\u2033 _builder_version=\u201d4.16\u2033 custom_padding=\u201d|||\u201d global_colors_info=\u201d{}\u201d custom_padding__hover=\u201d|||\u201d][et_pb_row_inner _builder_version=\u201d4.16\u2033 background_color=\u201d#00b2e2\u2033 custom_margin=\u201d41px||\u201d custom_margin_tablet=\u201d0px||\u201d custom_margin_phone=\u201d\u201d custom_margin_last_edited=\u201don|phone\u201d custom_padding=\u201d39.4375px|20px|0|20px|false|true\u201d animation_style=\u201dslide\u201d animation_direction=\u201dtop\u201d animation_intensity_slide=\u201d25%\u201d box_shadow_style=\u201dpreset1\u2033 box_shadow_blur=\u201d38px\u201d box_shadow_spread=\u201d-12px\u201d locked=\u201doff\u201d global_colors_info=\u201d{}\u201d][et_pb_column_inner saved_specialty_column_type=\u201d3_4\u2033 _builder_version=\u201d4.16\u2033 custom_padding=\u201d|||\u201d global_colors_info=\u201d{}\u201d custom_padding__hover=\u201d|||\u201d][et_pb_text admin_label=\u201dLonafarnib disponible pour la recherche\u201d _builder_version=\u201d4.18.1\u2033 header_2_line_height=\u201d1.2em\u201d background_layout=\u201ddark\u201d custom_margin=\u201d||35px\u201d custom_padding=\u201d|50px||\u201d custom_padding_tablet=\u201d|50px||50px||true\u201d custom_padding_phone=\u201d\u201d custom_padding_last_edited=\u201dsur|bureau\u201d header_font_size_tablet=\u201d\u201d header_font_size_phone=\u201d\u201d header_font_size_last_edited=\u201dsur|bureau\u201d header_2_font_size_tablet=\u201d25px\u201d header_2_font_size_phone=\u201d\u201d header_2_font_size_last_edited=\u201dsur|tablette\u201d header_4_font_size_tablet=\u201d\u201d header_4_font_size_phone=\u201d19px\u201d header_4_font_size_last_edited=\u201dsur|t\u00e9l\u00e9phone\u201d header_4_line_height_tablet=\u201d\u201d header_4_line_height_phone=\u201d1.2em\u201d header_4_line_height_last_edited=\u201dsur|t\u00e9l\u00e9phone\u201d z_index_tablet=\u201d500\u2033 global_colors_info=\u201d{}\u201d]<\/p>\n

Le lonafarnib disponible pour la recherche<\/strong><\/h2>\n

[\/et_pb_text][\/et_pb_column_inner][\/et_pb_row_inner][et_pb_row_inner custom_padding_last_edited=\u201don|phone\u201d _builder_version=\u201d4.16\u2033 custom_padding=\u201d|35px|0|0px|false|false\u201d custom_padding_tablet=\u201d|35px||35px||true\u201d custom_padding_phone=\u201d\u201d animation_direction=\u201dtop\u201d global_colors_info=\u201d{}\u201d][et_pb_column_inner saved_specialty_column_type=\u201d3_4\u2033 _builder_version=\u201d4.16\u2033 custom_padding=\u201d|||\u201d global_colors_info=\u201d{}\u201d custom_padding__hover=\u201d|||\u201d][et_pb_text disabled_on=\u201don|on|\u201d admin_label=\u201dTexte + Image\u201d _builder_version=\u201d4.18.1\u2033 header_4_line_height=\u201d1.2em\u201d header_4_font_size_tablet=\u201d\u201d header_4_font_size_phone=\u201d23px\u201d header_4_font_size_last_edited=\u201don|phone\u201d z_index_tablet=\u201d500\u2033 global_colors_info=\u201d{}\u201d]<\/p>\n

\"\"PRF met \u00e0 disposition de la communaut\u00e9 scientifique l'inhibiteur de la farn\u00e9syltransf\u00e9rase, le lonafarnib. Notre objectif est de soutenir les \u00e9tudes pr\u00e9cliniques visant \u00e0 \u00e9tudier plus en d\u00e9tail les effets du lonafarnib sur la prog\u00e9ria.<\/p>\n

La mission constante de PRF est de trouver de meilleurs traitements et un rem\u00e8de pour les enfants atteints de prog\u00e9ria. Il a \u00e9t\u00e9 d\u00e9montr\u00e9 que le lonafarnib est b\u00e9n\u00e9fique pour certains aspects de la maladie sur le plan clinique (Gordon et al, PNAS, 2012) et qu'il augmente la dur\u00e9e de vie (Gordon et al, Circulation, 2014) (Gordon et al, JAMA, 2018), mais il n'est pas curatif. \u00c0 mesure que de nouveaux compos\u00e9s sont identifi\u00e9s avec le potentiel d'am\u00e9liorer le HGPS, nous pr\u00e9voyons la n\u00e9cessit\u00e9 de tester ces compos\u00e9s en combinaison avec le lonafarnib in vitro et dans des mod\u00e8les animaux.<\/p>\n

 <\/p>\n

[\/et_pb_text][et_pb_image src=\u201dhttps:\/\/www.progeriaresearch.org\/wp-content\/uploads\/2019\/04\/Zoey-at-hospital-JAN-13-2014-1-261\u00d7300.jpg\u201d align=\u201dcenter\u201d align_tablet=\u201dcenter\u201d align_phone=\u201d\u201d align_last_edited=\u201don|desktop\u201d disabled_on=\u201d||on\u201d admin_label=\u201dImage (mobile uniquement)\u201d _builder_version=\u201d4.16\u2033 z_index_tablet=\u201d500\u2033 global_colors_info=\u201d{}\u201d][\/et_pb_image][et_pb_text disabled_on=\u201doff|off|on\u201d admin_label=\u201dTexte (mobile uniquement)\u201d _builder_version=\u201d4.18.1\u2033 header_4_line_height=\u201d1.2em\u201d header_4_font_size_tablet=\u201d\u201d header_4_font_size_phone=\u201d23px\u201d header_4_font_size_last_edited=\u201dsur|t\u00e9l\u00e9phone\u201d z_index_tablet=\u201d500\u2033 global_colors_info=\u201d{}\u201d]<\/p>\n

PRF met \u00e0 disposition de la communaut\u00e9 scientifique l'inhibiteur de la farn\u00e9syltransf\u00e9rase lonafarnib. Notre objectif est de soutenir les \u00e9tudes pr\u00e9cliniques visant \u00e0 \u00e9tudier plus en d\u00e9tail les effets du lonafarnib sur la prog\u00e9ria.<\/p>\n

La mission constante de PRF est de trouver de meilleurs traitements et un rem\u00e8de pour les enfants atteints de prog\u00e9ria. Il a \u00e9t\u00e9 d\u00e9montr\u00e9 que le lonafarnib est b\u00e9n\u00e9fique pour certains aspects de la maladie sur le plan clinique (Gordon et al, PNAS, 2012) et qu'il influence \u00e9galement l'allongement de la dur\u00e9e de vie estim\u00e9e (Gordon et al, Circulation, 2014) (Gordon et al, JAMA, 2018), mais il n'est pas curatif. \u00c0 mesure que de nouveaux compos\u00e9s sont identifi\u00e9s avec le potentiel d'am\u00e9liorer le HGPS, nous pr\u00e9voyons la n\u00e9cessit\u00e9 de tester ces compos\u00e9s en combinaison avec le lonafarnib in vitro et dans des mod\u00e8les animaux.<\/p>\n

[\/et_pb_text][\/et_pb_column_inner][\/et_pb_row_inner][et_pb_row_inner custom_padding_last_edited=\u201don|phone\u201d _builder_version=\u201d4.16\u2033 custom_padding=\u201d|35px|0|0px|false|false\u201d custom_padding_tablet=\u201d|35px||35px||true\u201d custom_padding_phone=\u201d\u201d animation_direction=\u201dtop\u201d global_colors_info=\u201d{}\u201d][et_pb_column_inner saved_specialty_column_type=\u201d3_4\u2033 _builder_version=\u201d4.16\u2033 custom_padding=\u201d|||\u201d global_colors_info=\u201d{}\u201d custom_padding__hover=\u201d|||\u201d][et_pb_text disabled_on=\u201don|on|\u201d admin_label=\u201dNotes techniques\u201d _builder_version=\u201d4.18.1\u2033 header_4_line_height=\u201d1.2em\u201d header_4_font_size_tablet=\u201d\u201d header_4_font_size_phone=\u201d23px\u201d header_4_font_size_last_edited=\u201don|phone\u201d z_index_tablet=\u201d500\u2033 box_shadow_horizontal_tablet=\u201d0px\u201d box_shadow_vertical_tablet=\u201d0px\u201d box_shadow_blur_tablet=\u201d40px\u201d box_shadow_spread_tablet=\u201d0px\u201d global_colors_info=\u201d{}\u201d]<\/p>\n

Notes techniques<\/strong><\/h4>\n

[\/et_pb_text][et_pb_button button_url=”https:\/\/www.progeriaresearch.org\/wp-content\/uploads\/2019\/09\/Lonafarnib-solubility.pdf” button_text=”Solubility PDF” admin_label=”Solubility PDF Button” _builder_version=”4.16″ background_layout=”dark” z_index_tablet=”500″ button_text_shadow_horizontal_length_tablet=”0px” button_text_shadow_vertical_length_tablet=”0px” button_text_shadow_blur_strength_tablet=”1px” box_shadow_horizontal_tablet=”0px” box_shadow_vertical_tablet=”0px” box_shadow_blur_tablet=”40px” box_shadow_spread_tablet=”0px” global_colors_info=”{}”][\/et_pb_button][et_pb_button button_url=”https:\/\/www.progeriaresearch.org\/wp-content\/uploads\/2019\/09\/Lonafarnib-administration-to-mice.pdf” button_text=”Administration PDF” admin_label=”Admin pdf button” _builder_version=”4.16″ background_layout=”dark” custom_margin=”20px|||” z_index_tablet=”500″ button_text_shadow_horizontal_length_tablet=”0px” button_text_shadow_vertical_length_tablet=”0px” button_text_shadow_blur_strength_tablet=”1px” box_shadow_horizontal_tablet=”0px” box_shadow_vertical_tablet=”0px” box_shadow_blur_tablet=”40px” box_shadow_spread_tablet=”0px” global_colors_info=”{}”][\/et_pb_button][\/et_pb_column_inner][\/et_pb_row_inner][et_pb_row_inner column_structure=”1_2,1_2″ custom_padding_last_edited=”on|phone” padding_left_right_link_1=”true” padding_left_right_link_2=”true” _builder_version=”4.16″ custom_margin=”39px||” custom_padding=”0|35px|30px|0px|false|false” custom_padding_tablet=”0px|35px||35px” custom_padding_phone=”0px||0px” animation_direction=”right” global_colors_info=”{}”][et_pb_column_inner type=”1_2″ saved_specialty_column_type=”3_4″ _builder_version=”4.16″ custom_padding=”|||” custom_padding_tablet=”|0px||0px” custom_padding_phone=”||30px” custom_padding_last_edited=”on|phone” global_colors_info=”{}” custom_padding__hover=”|||”][et_pb_text admin_label=”Ordering Information” _builder_version=”4.27.5″ header_4_line_height=”1.2em” hover_enabled=”0″ header_4_font_size_tablet=”” header_4_font_size_phone=”23px” header_4_font_size_last_edited=”on|phone” z_index_tablet=”500″ global_colors_info=”{}” sticky_enabled=”0″]<\/p>\n

Informations de commande<\/b><\/h4>\n

Le mat\u00e9riel est fourni gratuitement. Le destinataire paie tous les frais d'exp\u00e9dition. Pour recevoir du lonafarnib, veuillez remplir une demande et un accord de transfert de mat\u00e9riel, et les soumettre \u00e0 wnorris@brownhealth.org<\/a><\/p>\n

Demande et accord<\/a><\/p>\n

Accord de transfert de mat\u00e9riel pour les institutions non gouvernementales**<\/a><\/p>\n

**<\/strong>\u00a0PRF a une politique de\u00a0aucun changement \u00e0 notre MTA<\/strong>.<\/p>\n

[\/et_pb_text][\/et_pb_column_inner][et_pb_column_inner type=\u201d1_2\u2033 saved_specialty_column_type=\u201d3_4\u2033 _builder_version=\u201d4.16\u2033 custom_padding=\u201d|20px|30px|20px\u201d custom_padding_tablet=\u201d|0px||0px\u201d custom_padding_phone=\u201d||30px\u201d custom_padding_last_edited=\u201don|desktop\u201d global_colors_info=\u201d{}\u201d custom_padding__hover=\u201d|||\u201d][et_pb_image src=\u201dhttps:\/\/www.progeriaresearch.org\/wp-content\/uploads\/2019\/04\/FTI-graph.jpg\u201d align=\u201dcentre\u201d align_tablet=\u201dcentre\u201d align_phone=\u201d\u201d align_last_edited=\u201dsur|bureau\u201d _builder_version=\u201d4.16\u2033 animation_style=\u201ddiapositive\u201d animation_direction=\u201ddroite\u201d animation_intensity_slide=\u201d25%\u201d global_colors_info=\u201d{}\u201d]
\n[\/et_pb_image][\/et_pb_column_inner][\/et_pb_row_inner][et_pb_row_inner custom_padding_last_edited=”on|phone” padding_left_right_link_1=”true” padding_left_right_link_2=”true” _builder_version=”4.16″ custom_padding=”25px|35px|30px|0px|false|false” custom_padding_tablet=”0px|35px||35px” custom_padding_phone=”0px||0px” animation_style=”slide” animation_direction=”right” animation_intensity_slide=”25%” border_width_top=”10px” border_color_top=”#8fd2ed” border_width_bottom=”10px” border_color_bottom=”#29327a” global_colors_info=”{}”][et_pb_column_inner saved_specialty_column_type=”3_4″ _builder_version=”4.16″ custom_padding=”|||” custom_padding_tablet=”|0px||0px” custom_padding_phone=”||30px” custom_padding_last_edited=”on|phone” global_colors_info=”{}” custom_padding__hover=”|||”][et_pb_text admin_label=”Contacts for Questions and Assistance:” _builder_version=”4.27.2″ header_4_line_height=”1.2em” header_4_font_size_tablet=”” header_4_font_size_phone=”23px” header_4_font_size_last_edited=”on|phone” z_index_tablet=”500″ global_colors_info=”{}”]<\/p>\n

Contacts pour questions et assistance :<\/strong><\/h4>\n

Chercheur principal : Leslie B. Gordon, MD, PhD;\u00a0lgordon@progeriaresearch.org<\/a><\/p>\n

Banque de cellules et de tissus PRF : Wendy Norris ; wnorris@brownhealth.org<\/a><\/p>\n

Pour les institutions du gouvernement f\u00e9d\u00e9ral am\u00e9ricain ou pour toute question, veuillez contacter Wendy Norris, coordinatrice des \u00e9tudes de recherche, \u00e0 wnorris@brownhealth.org<\/a>\u00a0ou 401 274-1122 x 48063<\/span>.<\/p>\n

[\/et_pb_text][\/et_pb_column_inner][\/et_pb_row_inner][\/et_pb_column][\/et_pb_section][et_pb_section fb_built=\u201d1\u2033 module_class=\u201dfooter\u201d _builder_version=\u201d4.21.0\u2033 background_color=\u201d#29327a\u201d custom_margin=\u201d-2px|||||\u201d custom_padding=\u201d0|0px|0|0px|false|false\u201d z_index_tablet=\u201d500\u2033 border_width_top=\u201d12px\u201d border_color_top=\u201d#00b2e2\u2033 global_module=\u201d133\u2033 locked=\u201doff\u201d global_colors_info=\u201d{}\u201d][et_pb_row column_structure=\u201d1_4,1_4,1_2\u2033 make_equal=\u201don\u201d module_class=\u201d et_pb_row_fullwidth\u201d _builder_version=\u201d4.16\u2033 width=\u201d89%\u201d width_tablet=\u201d80%\u201d width_phone=\u201d\u201d width_last_edited=\u201don|desktop\u201d max_width=\u201d89%\u201d max_width_tablet=\u201d80%\u201d max_width_phone=\u201d\u201d max_width_last_edited=\u201don|desktop\u201d z_index_tablet=\u201d500\u2033 make_fullwidth=\u201don\u201d width_unit=\u201doff\u201d custom_width_percent=\u201d100%\u201d global_colors_info=\u201d{}\u201d][et_pb_column type=\u201d1_4\u2033 _builder_version=\u201d4.16\u2033 custom_padding=\u201d|||\u201d global_colors_info=\u201d{}\u201d custom_padding__hover=\u201d|||\u201d][et_pb_cta button_url=\u201dhttps:\/\/lp.constantcontactpages.com\/sl\/88gWWwz\u201d button_text=\u201dS'inscrire maintenant\u201d admin_label=\u201dS'inscrire aux mises \u00e0 jour\u201d module_class=\u201dsign-btn\u201d _builder_version=\u201d4.27.4\u2033 header_font_size=\u201d25px\u201d background_color=\u201d#29327a\u201d animation_style=\u201dslide\u201d animation_direction=\u201dleft\u201d animation_intensity_slide=\u201d25%\u201d link_option_url=\u201dhttps:\/\/lp.constantcontactpages.com\/sl\/88gWWwz\u201d header_font_size_tablet=\u201d\u201d header_font_size_phone=\u201d30px\u201d header_font_size_last_edited=\u201don|desktop\u201d z_index_tablet=\u201d500\u2033 border_radii=\u201don|25px|25px|25px|25px\u201d global_colors_info=\u201d{}\u201d button_bg_color__hover_enabled=\u201don\u201d button_bg_color__hover=\u201d#8fd2ed\u201d button_border_color__hover_enabled=\u201don\u201d]<\/p>\n

S'inscrire<\/h2>\n

pour notre<\/h2>\n

Mises \u00e0 jour\u00a0!<\/h2>\n

[\/et_pb_cta][\/et_pb_column][et_pb_column type=\u201d1_4\u2033 _builder_version=\u201d4.16\u2033 custom_padding=\u201d|||\u201d global_colors_info=\u201d{}\u201d custom_padding__hover=\u201d|||\u201d][et_pb_cta button_url=\u201dhttps:\/\/progeriaresearch.donorsupport.co\/-\/XZHJVWZR\u201d button_text=\u201dFaites un don maintenant\u201d admin_label=\u201dEnsemble, nous trouverons le rem\u00e8de !\u201d module_class=\u201dsign-btn\u201d _builder_version=\u201d4.16\u2033 header_font_size=\u201d25px\u201d background_color=\u201d#29327a\u201d animation_style=\u201dslide\u201d animation_direction=\u201dleft\u201d animation_intensity_slide=\u201d25%\u201d header_font_size_tablet=\u201d\u201d header_font_size_phone=\u201d30px\u201d header_font_size_last_edited=\u201don|desktop\u201d body_font_size_tablet=\u201d\u201d body_font_size_phone=\u201d\u201d body_font_size_last_edited=\u201don|desktop\u201d z_index_tablet=\u201d500\u2033 border_radii=\u201don|25px|25px|25px|25px\u201d global_colors_info=\u201d{}\u201d button_bg_color__hover_enabled=\u201don\u201d bouton_bg_color__hover=\u201d#8fd2ed\u201d bouton_border_color__hover_enabled=\u201don\u201d]<\/p>\n

Ensemble, nous<\/h2>\n

VOLONT\u00c9<\/em><\/h2>\n

trouve le rem\u00e8de !<\/h2>\n

[\/et_pb_cta][\/et_pb_column][et_pb_column type=”1_2″ _builder_version=”4.16″ custom_padding=”|||” global_colors_info=”{}” custom_padding__hover=”|||”][et_pb_image src=”https:\/\/www.progeriaresearch.org\/wp-content\/uploads\/2026\/03\/2026-footer-image-copy.png” title_text=”2026 footer image copy” _builder_version=”4.27.5″ _module_preset=”default” custom_margin=”35px||||false|false” global_colors_info=”{}”][\/et_pb_image][\/et_pb_column][\/et_pb_row][\/et_pb_section]<\/p>","protected":false},"excerpt":{"rendered":"

[et_pb_section fb_built=\u201d1\u2033 fullwidth=\u201don\u201d disabled_on=\u201doff|off|off\u201d _builder_version=\u201d4.16\u2033 border_width_bottom=\u201d55px\u201d border_color_bottom=\u201d#29327a\u201d locked=\u201doff\u201d global_colors_info=\u201d{}\u201d][et_pb_fullwidth_header _builder_version=\u201d4.18.1\u2033 title_font=\u201d||||||||\u201d title_font_size=\u201d55\u2033 background_color=\u201d#29327a\u201d background_image=\u201dhttps:\/\/www.progeriaresearch.org\/wp-content\/uploads\/2020\/12\/Aluisio.jpg\u201d background_position=\u201dcenter_left\u201d custom_padding=\u201d9vw||9vw||true\u201d custom_padding_tablet=\u201d\u201d custom_padding_phone=\u201d|56px||\u201d custom_padding_last_edited=\u201dsur|bureau\u201d title_font_size_tablet=\u201d45px\u201d title_font_size_phone=\u201d40px\u201d title_font_size_last_edited=\u201dsur|t\u00e9l\u00e9phone\u201d z_index_tablet=\u201d500\u2033 custom_css_main_element=\u201dbackground-position: center 18% !important;\u201d global_colors_info=\u201d{}\u201d] Programme d\u2019approvisionnement en m\u00e9dicaments pr\u00e9cliniques Lonafarnib [\/et_pb_fullwidth_header][\/et_pb_section][et_pb_section fb_built=\u201d1\u2033 use_custom_gutter=\u201don\u201d gutter_width=\u201d1\u2033 specialty=\u201don\u201d padding_left_1=\u201d35px\u201d padding_left_2=\u201d35px\u201d padding_2_tablet=\u201d|||0px\u201d padding_2_phone=\u201d|||0px\u201d padding_2_last_edited=\u201don|desktop\u201d module_class_1=\u201dsidebar-secondary-nav\u201d module_class=\u201dhandprint-bg\u201d _builder_version=\u201d4.16\u2033 background_image=\u201dhttps:\/\/www.progeriaresearch.org\/wp-content\/uploads\/2019\/04\/empreinte-de-main-bleue-uniquement.png\u201d parallax=\u201dactiv\u00e9\u201d parallax_method=\u201dd\u00e9sactiv\u00e9\u201d inner_width=\u201d100%\u201d inner_max_width=\u201d100%\u201d custom_padding=\u201d0|0px|54px|0px|false|false\u201d z_index_tablet=\u201d500\u2033 border_width_top=\u201d10px\u201d [\u2026]<\/p>","protected":false},"author":1,"featured_media":0,"parent":0,"menu_order":0,"comment_status":"closed","ping_status":"closed","template":"","meta":{"_et_pb_use_builder":"on","_et_pb_old_content":"\t\t\t\t[vc_row][vc_column][vc_custom_heading text=\"Lonafarnib Pre-clinical Drug Supply Program\" font_container=\"tag:h1|text_align:center\" use_theme_fonts=\"yes\"][vc_column_text]July 2015: Lonafarnib Now Available for Research<\/strong>\r\n\r\nPRF is making the farnesyltransferase inhibitor lonafarnib available to the research community. Our goal is to support preclinical studies to further investigate the effects of lonafarnib on Progeria.\r\n\r\nIt is PRF's steadfast mission to find better treatments and a cure for children with Progeria. Lonafarnib has been shown to benefit some aspects of the disease clinically, (Gordon et al, PNAS, 2012)\u00a0as well as influence increased estimated lifespan, (Gordon et al, Circulation, 2014)\u00a0but it is not curative. As new compounds are identified with the potential to ameliorate HGPS, we anticipate the need to test these compounds in combination with lonafarnib in vitro and in animal models.\r\n\r\nMany thanks to the pharmaceutical company Merck for making this program possible.<\/strong>\r\n\r\nOrdering Information<\/b>\r\n\r\nThe material is supplied at no cost.\u00a0 Recipient pays for all shipping charges.\r\n\r\nTo receive lonafarnib, please fill out an application and material transfer agreement, and submit to joan_brazier@brown.edu<\/a>\r\n\r\n<\/a>Application and Agreement<\/a>\r\n\r\nMaterial Transfer Agreement for Non-government Institutions<\/a>**\r\n\r\n**<\/strong> PRF has a policy of no changes to our MTA<\/strong>.\r\n\r\n<\/strong>\r\n\r\nContacts for Questions and Assistance:<\/strong>\r\n\r\nPrincipal Investigator: Leslie B. Gordon, MD, PhD; lgordon@progeriaresearch.org<\/a>\r\n\r\nResearch Study Coordinator: Joan Brazier; joan_brazier@brown.edu<\/a>\r\n\r\nFor U.S. Federal Government Institutions or questions, please contact Joan Brazier, Research Study Coordinator, at joan_brazier@brown.edu<\/a> or 401-863-9628.[\/vc_column_text][\/vc_column][\/vc_row]\t\t","_et_gb_content_width":"","footnotes":"","_links_to":"","_links_to_target":""},"class_list":["post-790","page","type-page","status-publish","hentry"],"yoast_head":"\nLonafarnib drug supply | The Progeria Research Foundation<\/title>\n<meta name=\"description\" content=\"PRF is making the farnesyltransferase inhibitor lonafarnib available to the research community. Our goal is to support preclinical studies to further investigate the effects of lonafarnib on Progeria.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.progeriaresearch.org\/fr\/lonafarnib-pre-clinical-drug-supply-program\/\" \/>\n<meta property=\"og:locale\" content=\"fr_FR\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Lonafarnib drug supply | The Progeria Research Foundation\" \/>\n<meta property=\"og:description\" content=\"PRF is making the farnesyltransferase inhibitor lonafarnib available to the research community. Our goal is to support preclinical studies to further investigate the effects of lonafarnib on Progeria.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.progeriaresearch.org\/fr\/lonafarnib-pre-clinical-drug-supply-program\/\" \/>\n<meta property=\"og:site_name\" content=\"The Progeria Research Foundation\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/ProgeriaResearch\/\" \/>\n<meta property=\"article:modified_time\" content=\"2026-03-17T15:43:56+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.progeriaresearch.org\/wp-content\/uploads\/2019\/04\/Zoey-at-hospital-JAN-13-2014-1.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"497\" \/>\n\t<meta property=\"og:image:height\" content=\"572\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:site\" content=\"@Progeria\" \/>\n<meta name=\"twitter:label1\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data1\" content=\"4 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\/\/www.progeriaresearch.org\/lonafarnib-pre-clinical-drug-supply-program\/\",\"url\":\"https:\/\/www.progeriaresearch.org\/lonafarnib-pre-clinical-drug-supply-program\/\",\"name\":\"Lonafarnib drug supply | The Progeria Research Foundation\",\"isPartOf\":{\"@id\":\"https:\/\/www.progeriaresearch.org\/ta\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/www.progeriaresearch.org\/lonafarnib-pre-clinical-drug-supply-program\/#primaryimage\"},\"image\":{\"@id\":\"https:\/\/www.progeriaresearch.org\/lonafarnib-pre-clinical-drug-supply-program\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/www.progeriaresearch.org\/wp-content\/uploads\/2019\/04\/Zoey-at-hospital-JAN-13-2014-1-261x300.jpg\",\"datePublished\":\"2017-02-26T19:12:39+00:00\",\"dateModified\":\"2026-03-17T15:43:56+00:00\",\"description\":\"PRF is making the farnesyltransferase inhibitor lonafarnib available to the research community. Our goal is to support preclinical studies to further investigate the effects of lonafarnib on Progeria.\",\"breadcrumb\":{\"@id\":\"https:\/\/www.progeriaresearch.org\/lonafarnib-pre-clinical-drug-supply-program\/#breadcrumb\"},\"inLanguage\":\"fr-FR\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/www.progeriaresearch.org\/lonafarnib-pre-clinical-drug-supply-program\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"fr-FR\",\"@id\":\"https:\/\/www.progeriaresearch.org\/lonafarnib-pre-clinical-drug-supply-program\/#primaryimage\",\"url\":\"https:\/\/www.progeriaresearch.org\/wp-content\/uploads\/2019\/04\/Zoey-at-hospital-JAN-13-2014-1-261x300.jpg\",\"contentUrl\":\"https:\/\/www.progeriaresearch.org\/wp-content\/uploads\/2019\/04\/Zoey-at-hospital-JAN-13-2014-1-261x300.jpg\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/www.progeriaresearch.org\/lonafarnib-pre-clinical-drug-supply-program\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/www.progeriaresearch.org\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Lonafarnib Pre-clinical Drug Supply Program\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/www.progeriaresearch.org\/ta\/#website\",\"url\":\"https:\/\/www.progeriaresearch.org\/ta\/\",\"name\":\"The Progeria Research Foundation\",\"description\":\"For the Children \u2665 For the Cure\",\"publisher\":{\"@id\":\"https:\/\/www.progeriaresearch.org\/ta\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/www.progeriaresearch.org\/ta\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"fr-FR\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/www.progeriaresearch.org\/ta\/#organization\",\"name\":\"The Progeria Research Foundation\",\"url\":\"https:\/\/www.progeriaresearch.org\/ta\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"fr-FR\",\"@id\":\"https:\/\/www.progeriaresearch.org\/ta\/#\/schema\/logo\/image\/\",\"url\":\"https:\/\/www.progeriaresearch.org\/wp-content\/uploads\/2019\/05\/PRF_Logo_2019_optimized.png\",\"contentUrl\":\"https:\/\/www.progeriaresearch.org\/wp-content\/uploads\/2019\/05\/PRF_Logo_2019_optimized.png\",\"width\":300,\"height\":86,\"caption\":\"The Progeria Research Foundation\"},\"image\":{\"@id\":\"https:\/\/www.progeriaresearch.org\/ta\/#\/schema\/logo\/image\/\"},\"sameAs\":[\"https:\/\/www.facebook.com\/ProgeriaResearch\/\",\"https:\/\/x.com\/Progeria\",\"https:\/\/www.instagram.com\/progeriaresearch\/\"]}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Lonafarnib drug supply | The Progeria Research Foundation","description":"PRF met \u00e0 disposition de la communaut\u00e9 scientifique l'inhibiteur de la farn\u00e9syltransf\u00e9rase lonafarnib. Notre objectif est de soutenir les \u00e9tudes pr\u00e9cliniques visant \u00e0 \u00e9tudier plus en d\u00e9tail les effets du lonafarnib sur la prog\u00e9ria.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.progeriaresearch.org\/fr\/lonafarnib-pre-clinical-drug-supply-program\/","og_locale":"fr_FR","og_type":"article","og_title":"Lonafarnib drug supply | The Progeria Research Foundation","og_description":"PRF is making the farnesyltransferase inhibitor lonafarnib available to the research community. Our goal is to support preclinical studies to further investigate the effects of lonafarnib on Progeria.","og_url":"https:\/\/www.progeriaresearch.org\/fr\/lonafarnib-pre-clinical-drug-supply-program\/","og_site_name":"The Progeria Research Foundation","article_publisher":"https:\/\/www.facebook.com\/ProgeriaResearch\/","article_modified_time":"2026-03-17T15:43:56+00:00","og_image":[{"width":497,"height":572,"url":"https:\/\/www.progeriaresearch.org\/wp-content\/uploads\/2019\/04\/Zoey-at-hospital-JAN-13-2014-1.jpg","type":"image\/jpeg"}],"twitter_card":"summary_large_image","twitter_site":"@Progeria","twitter_misc":{"Est. reading time":"4 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/www.progeriaresearch.org\/lonafarnib-pre-clinical-drug-supply-program\/","url":"https:\/\/www.progeriaresearch.org\/lonafarnib-pre-clinical-drug-supply-program\/","name":"Lonafarnib drug supply | The Progeria Research Foundation","isPartOf":{"@id":"https:\/\/www.progeriaresearch.org\/ta\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.progeriaresearch.org\/lonafarnib-pre-clinical-drug-supply-program\/#primaryimage"},"image":{"@id":"https:\/\/www.progeriaresearch.org\/lonafarnib-pre-clinical-drug-supply-program\/#primaryimage"},"thumbnailUrl":"https:\/\/www.progeriaresearch.org\/wp-content\/uploads\/2019\/04\/Zoey-at-hospital-JAN-13-2014-1-261x300.jpg","datePublished":"2017-02-26T19:12:39+00:00","dateModified":"2026-03-17T15:43:56+00:00","description":"PRF met \u00e0 disposition de la communaut\u00e9 scientifique l'inhibiteur de la farn\u00e9syltransf\u00e9rase lonafarnib. Notre objectif est de soutenir les \u00e9tudes pr\u00e9cliniques visant \u00e0 \u00e9tudier plus en d\u00e9tail les effets du lonafarnib sur la prog\u00e9ria.","breadcrumb":{"@id":"https:\/\/www.progeriaresearch.org\/lonafarnib-pre-clinical-drug-supply-program\/#breadcrumb"},"inLanguage":"fr-FR","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.progeriaresearch.org\/lonafarnib-pre-clinical-drug-supply-program\/"]}]},{"@type":"ImageObject","inLanguage":"fr-FR","@id":"https:\/\/www.progeriaresearch.org\/lonafarnib-pre-clinical-drug-supply-program\/#primaryimage","url":"https:\/\/www.progeriaresearch.org\/wp-content\/uploads\/2019\/04\/Zoey-at-hospital-JAN-13-2014-1-261x300.jpg","contentUrl":"https:\/\/www.progeriaresearch.org\/wp-content\/uploads\/2019\/04\/Zoey-at-hospital-JAN-13-2014-1-261x300.jpg"},{"@type":"BreadcrumbList","@id":"https:\/\/www.progeriaresearch.org\/lonafarnib-pre-clinical-drug-supply-program\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.progeriaresearch.org\/"},{"@type":"ListItem","position":2,"name":"Lonafarnib Pre-clinical Drug Supply Program"}]},{"@type":"WebSite","@id":"https:\/\/www.progeriaresearch.org\/ta\/#website","url":"https:\/\/www.progeriaresearch.org\/ta\/","name":"La Fondation de recherche sur la prog\u00e9ria","description":"Pour les enfants \u2665 Pour la gu\u00e9rison","publisher":{"@id":"https:\/\/www.progeriaresearch.org\/ta\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.progeriaresearch.org\/ta\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"fr-FR"},{"@type":"Organization","@id":"https:\/\/www.progeriaresearch.org\/ta\/#organization","name":"La Fondation de recherche sur la prog\u00e9ria","url":"https:\/\/www.progeriaresearch.org\/ta\/","logo":{"@type":"ImageObject","inLanguage":"fr-FR","@id":"https:\/\/www.progeriaresearch.org\/ta\/#\/schema\/logo\/image\/","url":"https:\/\/www.progeriaresearch.org\/wp-content\/uploads\/2019\/05\/PRF_Logo_2019_optimized.png","contentUrl":"https:\/\/www.progeriaresearch.org\/wp-content\/uploads\/2019\/05\/PRF_Logo_2019_optimized.png","width":300,"height":86,"caption":"The Progeria Research Foundation"},"image":{"@id":"https:\/\/www.progeriaresearch.org\/ta\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/ProgeriaResearch\/","https:\/\/x.com\/Progeria","https:\/\/www.instagram.com\/progeriaresearch\/"]}]}},"_links":{"self":[{"href":"https:\/\/www.progeriaresearch.org\/fr\/wp-json\/wp\/v2\/pages\/790","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.progeriaresearch.org\/fr\/wp-json\/wp\/v2\/pages"}],"about":[{"href":"https:\/\/www.progeriaresearch.org\/fr\/wp-json\/wp\/v2\/types\/page"}],"author":[{"embeddable":true,"href":"https:\/\/www.progeriaresearch.org\/fr\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.progeriaresearch.org\/fr\/wp-json\/wp\/v2\/comments?post=790"}],"version-history":[{"count":2,"href":"https:\/\/www.progeriaresearch.org\/fr\/wp-json\/wp\/v2\/pages\/790\/revisions"}],"predecessor-version":[{"id":21465,"href":"https:\/\/www.progeriaresearch.org\/fr\/wp-json\/wp\/v2\/pages\/790\/revisions\/21465"}],"wp:attachment":[{"href":"https:\/\/www.progeriaresearch.org\/fr\/wp-json\/wp\/v2\/media?parent=790"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}